These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f. Harvey H; Piskareva O; Creevey L; Alcock LC; Buckley PG; O'Sullivan MJ; Segura MF; Gallego S; Stallings RL; Bray IM Int J Cancer; 2015 Apr; 136(7):1579-88. PubMed ID: 25137037 [TBL] [Abstract][Full Text] [Related]
43. Antibody therapy and neuroblastoma. Tao X N Engl J Med; 2011 Jan; 364(3):289; author reply 289-90. PubMed ID: 21247330 [No Abstract] [Full Text] [Related]
44. [Survival of children and results obtained with a new chemotherapic combination in disseminated neuroblastoma treatment (author's transl)]. Padulles J; Prats J; Martínez-Mora J; Boix Ochoa J; Ferres F An Esp Pediatr; 1976 Nov; 9(8):33-5. PubMed ID: 65139 [TBL] [Abstract][Full Text] [Related]
45. Therapeutic implications of the uptake of radiolabelled mIBG for the treatment of neuroblastoma. O'Donoghue JA; Wheldon TE; Babich JW; Moyes JS; Barrett A; Meller ST Prog Clin Biol Res; 1991; 366():455-61. PubMed ID: 2068160 [No Abstract] [Full Text] [Related]
46. [Treatment of malignant tumors in infants with antineoplastic agents]. Taguchi N Naika; 1968 Sep; 22(3):634-9. PubMed ID: 4303515 [No Abstract] [Full Text] [Related]
47. Pediatric cancer forum examines chemotherapy variables. Volkers N J Natl Cancer Inst; 1991 Dec; 83(23):1714-5. PubMed ID: 1770549 [No Abstract] [Full Text] [Related]
48. Pharmacokinetics and pharmacogenetics of 13-cis-retinoic acid in the treatment of neuroblastoma. Veal G; Rowbotham S; Boddy A Therapie; 2007; 62(2):91-3. PubMed ID: 17582307 [TBL] [Abstract][Full Text] [Related]
49. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. Munoz M; Henderson M; Haber M; Norris M IUBMB Life; 2007 Dec; 59(12):752-7. PubMed ID: 18085475 [TBL] [Abstract][Full Text] [Related]
50. [Molecular biology markers of neuroblastoma as the basis for a therapy concept]. Girgert R; Treuner J; Schweizer P Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():1053-5. PubMed ID: 9101780 [TBL] [Abstract][Full Text] [Related]
56. Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Moreno L; Caron H; Geoerger B; Eggert A; Schleiermacher G; Brock P; Valteau-Couanet D; Chesler L; Schulte JH; De Preter K; Molenaar J; Schramm A; Eilers M; Van Maerken T; Johnsen JI; Garrett M; George SL; Tweddle DA; Kogner P; Berthold F; Koster J; Barone G; Tucker ER; Marshall L; Herold R; Sterba J; Norga K; Vassal G; Pearson AD Expert Opin Drug Discov; 2017 Aug; 12(8):801-811. PubMed ID: 28604107 [TBL] [Abstract][Full Text] [Related]
57. [Solid tumors in childhood. With special reference to cytostatic treatment]. Dombernowsky P; Nissen NI; Hansen HH; Pedersen-Bjergaard J Ugeskr Laeger; 1978 Feb; 140(7):335-40. PubMed ID: 204092 [No Abstract] [Full Text] [Related]
58. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma. Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791 [TBL] [Abstract][Full Text] [Related]
60. Results of treatment with 131 I-metaiodobenzylguanidine (131 I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy. Voûte PA; Hoefnagel CA; de Kraker J; Valdes Olmos R; Bakker DJ; van de Kleij AJ Prog Clin Biol Res; 1991; 366():439-45. PubMed ID: 2068157 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]